/KURA
KURA Stock - Kura Oncology, Inc.
Healthcare|BiotechnologyNASDAQ
$9.84-0.10%
$0.01 (-0.10%) • Dec 19
82
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
High Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.66
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+259.0%upside
Target: $35.33
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for KURA
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$9.74 – $9.94
TARGET (TP)$35.33
STOP LOSS$9.05
RISK/REWARD1:32.3
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.21
52W High$12.49
52W Low$5.41
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $53.88M | N/A | N/A | N/A | N/A |
| Gross Profit | $53.88M | $-849,000 | N/A | N/A | $-194,000 |
| Gross Margin | 100.0% | N/A | N/A | N/A | N/A |
| Operating Income | $-193,195,000 | $-165,804,000 | $-139,865,000 | $-131,258,000 | $-91,899,000 |
| Net Income | $-173,983,000 | $-152,631,000 | $-135,840,000 | $-130,466,000 | $-89,625,000 |
| Net Margin | -322.9% | N/A | N/A | N/A | N/A |
| EPS | $-2.02 | $-2.08 | $-2.03 | $-1.97 | $-1.69 |
Company Overview
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, a small molecule inhibitor of the menin-Lysine K-specific Methyltransferase 2A protein-protein interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; and tipifarnib, an orally bioavailable inhibitor of farnesyl transferase that is in Phase II clinical trials for the treatment of solid tumors and hematologic indications. The company has a clinical collaboration with Novartis to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression or PIK3CA mutation and/or amplification. Kura Oncology, Inc. was founded in 2014 and is headquartered in San Diego, California.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
5
63%
Hold / Neutral
3
38%
Sell / Underperform
0%
Analyst Consensus🟡 Mixed
5 Bullish3 Neutral/Bearish
Price Targets
$25
Average Target
↑ 153.4% Upside
Now
$11
Low
$25
Average
$31
High
Based on 8 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| September 4th 2025 | Guggenheim | Initiation | Neutral | - |
| February 6th 2025 | BTIG Research | Downgrade | Neutral | - |
| October 24th 2024 | UBS | Initiation | Buy | $27 |
| October 14th 2024 | Stifel | Downgrade | Hold | $19← $26 |
| December 22nd 2023 | Mizuho | Initiation | Buy | $26 |
| August 11th 2023 | BofA Securities | Initiation | Buy | $31 |
| July 27th 2023 | Scotiabank | Initiation | Sector Perform | $10.5 |
| May 17th 2023 | BTIG Research | Initiation | Buy | $31 |
| January 31st 2023 | Stifel | Initiation | Buy | $25 |
| July 12th 2022 | Cantor Fitzgerald | Initiation | Overweight | $30 |
Earnings History & Surprises
KURABeat Rate
67%
Last 18 quarters
Avg Surprise
-30.1%
EPS vs Estimate
Beats / Misses
12/5
1 met exactly
Latest EPS
$-0.85
Q4 2025
EPS Surprise History
Q1 24
+1.8%
$-0.55vs$-0.56
Q2 24
-5.4%
$-0.59vs$-0.56
Q3 24
+6.3%
$-0.59vs$-0.63
Q4 24
+1.6%
$-0.63vs$-0.64
Q1 25
+66.2%
$-0.22vs$-0.65
Q2 25
-29.4%
$-0.66vs$-0.51
Q3 25
-600.0%
$-0.75vs$0.15
Q4 25
-49.1%
$-0.85vs$-0.57
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | Apr 29, 2026 | — | — | — | — |
Q1 2026 | Feb 25, 2026 | $0.21 | — | — | — |
Q4 2025 | Nov 4, 2025 | $-0.57 | $-0.85 | -49.1% | ✗ MISS |
Q3 2025 | Aug 7, 2025 | $0.15 | $-0.75 | -600.0% | ✗ MISS |
Q2 2025 | May 1, 2025 | $-0.51 | $-0.66 | -29.4% | ✗ MISS |
Q1 2025 | Feb 26, 2025 | $-0.65 | $-0.22 | +66.2% | ✓ BEAT |
Q4 2024 | Nov 7, 2024 | $-0.64 | $-0.63 | +1.6% | ✓ BEAT |
Q3 2024 | Aug 8, 2024 | $-0.63 | $-0.59 | +6.3% | ✓ BEAT |
Q2 2024 | May 2, 2024 | $-0.56 | $-0.59 | -5.4% | ✗ MISS |
Q1 2024 | Feb 27, 2024 | $-0.56 | $-0.55 | +1.8% | ✓ BEAT |
Q4 2023 | Nov 2, 2023 | $-0.56 | $-0.50 | +10.7% | ✓ BEAT |
Q3 2023 | Aug 3, 2023 | $-0.57 | $-0.53 | +7.0% | ✓ BEAT |
Q2 2023 | May 10, 2023 | $-0.54 | $-0.50 | +7.4% | ✓ BEAT |
Q1 2023 | Feb 23, 2023 | $-0.58 | $-0.49 | +15.5% | ✓ BEAT |
Q4 2022 | Nov 3, 2022 | $-0.57 | $-0.53 | +7.0% | ✓ BEAT |
Q3 2022 | Aug 3, 2022 | $-0.52 | $-0.52 | 0.0% | = MET |
Q2 2022 | May 4, 2022 | $-0.52 | $-0.49 | +5.8% | ✓ BEAT |
Q1 2022 | Feb 24, 2022 | $-0.54 | $-0.49 | +9.3% | ✓ BEAT |
Q4 2021 | Nov 4, 2021 | $-0.54 | $-0.50 | +7.4% | ✓ BEAT |
Q3 2021 | Aug 5, 2021 | $-0.49 | $-0.51 | -4.1% | ✗ MISS |
Latest News
Kura Oncology and Kyowa Kirin Report KOMZIFTI Data In AML, Showing High Remission Rates In Newly Diagnosed NPM1-m Patients, Strong Responses In Relapsed/Refractory NPM1-m And KMT2A-r AML, Favorable Safety Profile With Venetoclax/Azacitidine Triplet And Ongoing Registrational Trials Across Multiple Front-Line And R/R AML Subtypes
📈 PositiveBenzinga•Dec 8, 2025, 03:33 PM•Also:
Kura Oncology To Host Dec. 8 Virtual Investor Event On Triplet Therapy Data For AML Ahead Of ASH 2025
➖ NeutralBenzinga•Dec 3, 2025, 01:35 PM
Kura Oncology And Kyowa Kirin Announce NCCN Inclusion Of Newly FDA-Approved KOMZIFTI As Recommended Treatment For Relapsed/Refractory AML With NPM1 Mutation
📈 PositiveBenzinga•Nov 25, 2025, 10:18 PM•Also:
Barclays Maintains Overweight on Kura Oncology, Raises Price Target to $28
📈 PositiveBenzinga•Nov 24, 2025, 02:32 PM•Also:
UBS Maintains Buy on Kura Oncology, Raises Price Target to $16
📈 PositiveBenzinga•Nov 14, 2025, 05:13 PM
Wedbush Maintains Outperform on Kura Oncology, Raises Price Target to $38
📈 PositiveBenzinga•Nov 14, 2025, 03:15 PM
Kura Oncology Exec Says: Already In Dialog With FDA About Potential Steps Post Approval That Could Help Refine Labeling
📈 PositiveBenzinga•Nov 13, 2025, 06:07 PM
Trading Halt: Halt status updated at 11:25:00 AM ET: Quotation Resumption: News and Resumption Times
➖ NeutralBenzinga•Nov 13, 2025, 04:25 PM
FDA Approves Ziftomenib For Relapsed Or Refractory Acute Myeloid Leukemia With A NPM1 Mutation
📈 PositiveBenzinga•Nov 13, 2025, 03:15 PM
Trading Halt: Halted at 9:59:53 a.m. ET - Trading Halt: Halt News Pending
➖ NeutralBenzinga•Nov 13, 2025, 02:59 PM
Kura Oncology Q3 EPS $(0.85) Misses $(0.84) Estimate, Sales $20.750M Miss $41.259M Estimate
📉 NegativeBenzinga•Nov 4, 2025, 11:34 AM
Kura Oncology Gets $30M Milestone Payment Under Partnership Agreement With Kyowa Kirin In Dosing First Participant In Second KOMET-017 Phase 3 Registration Trials Of Ziftomenib
📈 PositiveBenzinga•Nov 3, 2025, 09:11 PM•Also:
Kura Oncology To Feature Results From KOMET-007 Combination Trial Of Ziftomenib, Oral Investigational Menin Inhibitor, At ASH 2025
📈 PositiveBenzinga•Nov 3, 2025, 02:25 PM
Kura Oncology Receives $30M Development Milestone Payment Under Its Collaboration With Kyowa Kirin From Dosing First Patient In KOMET-017 Phase 3 Trial
📈 PositiveBenzinga•Oct 24, 2025, 11:03 AM•Also:
JMP Securities Reiterates Market Outperform on Kura Oncology, Maintains $24 Price Target
📈 PositiveBenzinga•Oct 20, 2025, 01:37 PM
HC Wainwright & Co. Reiterates Buy on Kura Oncology, Maintains $40 Price Target
📈 PositiveBenzinga•Oct 20, 2025, 11:49 AM
Reported Saturday, Kura Oncology Presents New ESMO 2025 Data Showing Darlifarnib Plus Cabozantinib Delivers 50% ORR In RCC; FTI Programs Demonstrate Robust Activity And Manageable Safety Profile
📈 PositiveBenzinga•Oct 20, 2025, 08:19 AM
Kura Oncology And Kyowa Kirin Announce Dosing Of First Patient In Cohort Of KOMET-007 Clinical Trial
➖ NeutralBenzinga•Oct 1, 2025, 11:11 AM•Also:
HC Wainwright & Co. Reiterates Buy on Kura Oncology, Maintains $40 Price Target
📈 PositiveBenzinga•Sep 30, 2025, 10:54 AM
Kura Oncology And Kyowa Kirin Dose First Patient In Phase 3 KOMET-017 Trial Of Ziftomenib For Frontline Acute Myeloid Leukemia
📈 PositiveBenzinga•Sep 29, 2025, 08:01 PM•Also:
Frequently Asked Questions about KURA
What is KURA's current stock price?
Kura Oncology, Inc. (KURA) is currently trading at $9.84 per share. The stock has moved -0.10% today.
What is the analyst price target for KURA?
The average analyst price target for KURA is $35.33, based on 1 analyst.
What sector is Kura Oncology, Inc. in?
Kura Oncology, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is KURA's market cap?
Kura Oncology, Inc. has a market capitalization of $0.86 billion, making it a small-cap company.
Does KURA pay dividends?
No, Kura Oncology, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorBCAX
Bicara Therapeutics Inc. Common Stock
$17.60
Mkt Cap: $1.0B
EYPT
EyePoint Pharmaceuticals, Inc.
$17.43
Mkt Cap: $1.2B
MRVI
Maravai LifeSciences Holdings, Inc.
$3.43
Mkt Cap: $0.5B
PRME
Prime Medicine, Inc.
$3.64
Mkt Cap: $0.6B
PROK
ProKidney Corp.
$2.37
Mkt Cap: $0.3B
REPL
Replimune Group, Inc.
$9.88
Mkt Cap: $0.8B
RZLT
Rezolute, Inc.
$1.77
Mkt Cap: $0.2B
SVRA
Savara Inc.
$6.05
Mkt Cap: $1.2B
TNGX
Tango Therapeutics, Inc.
$8.52
Mkt Cap: $0.9B
TYRA
Tyra Biosciences, Inc.
$25.51
Mkt Cap: $1.4B
Explore stocks similar to KURA for comparison